The European Union has launched its largest Chips Act pilot line, NanoIC, at IMEC Leuven, a major milestone for European semiconductor development and manufacturing. With a total investment of €2.5 billion, the facility has received €700 million in EU funding, €700 million from national and regional governments, and the remainder from ASML and other industry partners. NanoIC will …
The Commission is inviting input on the evaluation of the Biocidal Products Regulation (BPR), through a Call for Evidence and public consultation published. The call and consultation are open to citizens, companies, industry associations, Member States competent authorities, NGOs, and other interested parties that wish to give their views. The public consultation questionnaire is divided into two parts, …
The European Commission welcomes the political agreement to modernise the EU’s pharmaceutical legislation, reached by the Council and the European Parliament. The reform is a crucial step in boosting innovation and investment in the EU’s pharmaceutical sector, while ensuring that medicines are safe, effective and available for patients throughout Europe. The reform package revises the current EU …
A new report published as part of the State of Health in the EU shows Europe urgently needs innovative and resilient health systems to improve healthcare and boost competitiveness. With pressing challenges such as ageing populations and non-communicable diseases, EU Member States are now advancing and putting in place critical reforms, supported by EU funding. Today’s Synthesis Report …
The Commission has launched a public consultation on health hazards and risks associated with the use of brain stimulators for non-medical purpose. Participants to the consultation are asked to comment on the preliminary opinion of the Scientific Committee on Health, Environmental and Emerging Risks (SCHEER) on this issue. The SCHEER preliminary opinion suggests strong evidence that non-invasive …
The European Commission has published an interim evaluation of the EU4Health Programme, the largest and most ambitious EU health funding programme ever. With a budget of €4.6 billion over the 2021-2027 period, EU4Health has made a significant contribution to the EU’s post COVID recovery, by supporting Member States in building more resilient and accessible healthcare systems …
The European Union is boosting its health preparedness architecture through the new Union prevention, preparedness and response plan for health crises. It will provide policymakers, crisis managers, and stakeholders with practical tools, such as exchanging information, expertise and technical assistance when a crisis occurs, for coordinated action in times of health crises to protect the health …
On Friday 28 November, the annual HTA Work Programme for 2026 was adopted by the Member State Coordination Group on Health Technology Assessment (HTACG). The Work Programme outlines the key activities and strategic priorities of the group for the upcoming year. The HTACG estimates that it will initiate around 50 joint clinical assessments (JCAs) of …
The Commission granted EU marketing authorisation for ‘brensocatib’, a new active substance for the treatment of chronic progressive lung disease (non-cystic fibrosis bronchiectasis, or NCFB) in patients aged 12 years and older. The estimated number of patients with NCFB in the EU ranges from 400,000 to three million. The disease causes damaged airways and severe …
Call for applications Member States, supported by the European Commission, are pleased to announce the launch of a pilot coordinated assessment of clinical investigations and performance studies across multiple Member States as per Articles 78 of the Regulation (EU) 2017/745 (MDR) and 74 of the Regulation (EU) 2017/746 (IVDR) respectively. This pilot will allow sponsors …